• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

    4/8/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRMY alert in real time by email

    Data to be Presented at the Hot Topics in Child Neurology Podium Presentation Session at the American Academy of Neurology Annual Meeting

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the presentation of updated data from its Open-Label Extension (OLE) study (ZYN2-CL-017) evaluating the safety and effectiveness of ZYN002 in children, adolescents, and adults with Fragile X syndrome (FXS). The data showed clinically meaningful improvements in irritability-related symptoms prevalent in individuals with FXS. There are currently no U.S. Food & Drug Administration (FDA) approved treatments for FXS.

    The data will be shared during a podium presentation at the American Academy of Neurology (AAN) 2025 Annual Meeting's "Hot Topics in Child Neurology" session on Tuesday, April 8, 2025, at 3:30 PM PT in San Diego, CA.

    "The acceptance of our Fragile X syndrome OLE data as a podium presentation at AAN underlines the significant unmet need in FXS, and the potential for ZYN002 to become the first-and-only approved treatment for this condition," said Kumar Budur, MD, MS, Chief Medical and Scientific Officer at Harmony Biosciences. "These data are encouraging as we prepare for the topline data readout from our ongoing Phase 3 registrational trial, the RECONNECT study, in Q3 2025. Approximately 80,000 individuals are living with this rare neurological disease in the U.S. alone and Harmony is deeply committed to addressing the profound unmet medical needs of this community both in the U.S. and globally."

    Participants entered the OLE trial from the Phase 2/3 CONNECT-FX trial, and the Phase 1/2 FAB-C signal detection open-label trial. Participants in the OLE trial demonstrated clinically meaningful improvements in behavioral symptoms as measured by the Aberrant Behavior Checklist – Community (ABC-CFXS Irritability). This included participants who received active treatment in the double-blind, placebo-controlled CONNECT-FX trial, and those who transitioned from placebo to treatment in the OLE. More than 60% of participants in both groups achieved clinically meaningful improvement of at least 9 points on the ABC-CFXS Irritability scores at two consecutive visits.

    Additionally, 40.6% of participants who received active treatment in the CONNECT-FX trial were rated by their caregivers as demonstrating a clinically meaningful improvement in behavior based on the Caregiver Global Impression of Change (CaGI-C) scores, compared to 29.8% who received placebo in the CONNECT-FX trial. After three years, 73.3% of patients who continued on ZYN002, as well as 72% who transitioned from placebo to ZYN002, experienced clinically meaningful improvements.

    Serious treatment-emergent adverse events were reported in 4.6% of patients in the OLE, with discontinuation occurring in 3.3% of patients. Treatment-related adverse events were observed in 12.9% of patients, none of which were serious, and the most common of these adverse events was pain at the treatment application site in 6.7% of patients.

    The data presented at AAN covers the period from September 2018 to January 31, 2024, and included 240 patients administered ZYN002 at doses of 250, 500, or 750 mg per day based on their weight. The mean age of the patients was 9.7 years and ranged from 3 to 17 years.

    ZYN002 is currently being evaluated as an investigational treatment for FXS in the RECONNECT study, a Phase 3 randomized, double-blind, placebo-controlled registrational trial evaluating the safety and efficacy of ZYN002 in patients with FXS ages 3 to under 30 years. ZYN002 is not approved by the FDA for the treatment of FXS.

    About ZYN002

    ZYN002 is the first-and-only pharmaceutically manufactured synthetic cannabidiol devoid of THC and formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. The product is manufactured through a synthetic process in a cGMP facility and is not extracted from the cannabis plant. ZYN002 does not contain THC, the compound that causes the euphoric effect of cannabis, and has the potential to be a nonscheduled product if approved. Cannabidiol, the active ingredient in ZYN002, has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of FXS and for the treatment of 22q11.2 deletion syndrome (22q). Additionally, ZYN002 has received FDA Fast Track designation for the treatment of behavioral symptoms in patients with FXS.

    About Fragile X Syndrome

    Fragile X syndrome (FXS) is a rare genetic disorder that is the leading known inherited cause of both intellectual disability and autism spectrum disorder. The disorder negatively affects synaptic function, plasticity and neuronal connections, and results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability. While the exact prevalence is unknown, upwards of 80,000 patients in the U.S. and 121,000 patients in the European Union and the UK are believed to have FXS, based on FXS prevalence estimates of approximately 1 in 4,000 to 7,000 in males and approximately 1 in 8,000 to 11,000 in females. There is a significant unmet medical need in patients living with FXS as there are currently no FDA-approved treatments for this disorder.

    FXS is caused by a mutation in FMR1, a gene which modulates a number of systems, including the endocannabinoid system, and most critically, codes for a protein called FMRP. The FMR1 mutation manifests as multiple repeats of a DNA segment, known as the CGG triplet repeat, resulting in deficiency or lack of FMRP. FMRP helps regulate the production of other proteins and plays a role in the development of synapses, which are critical for relaying nerve impulses, and in regulating synaptic plasticity. In people with full mutation of the FMR1 gene, the CGG segment is repeated more than 200 times, and in most cases causes the gene to not function. Methylation of the FMR1 gene also plays a role in determining functionality of the gene. In approximately 60% of patients with FXS, who have complete methylation of the FMR1 gene, no FMRP is produced, resulting in dysregulation of the systems modulated by FMRP.

    About Harmony Biosciences

    Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the timing of, and our ability to obtain, regulatory approvals for our product candidates; our estimates regarding expenses, future revenue, capital requirements and additional financing needs; our ability to identify, acquire and integrate additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and manufacturing capabilities and strategy; significant competition in our industry; our intellectual property position; loss or retirement of key members of management; failure to successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the impact of government laws and regulations; volatility and fluctuations in the price of our common stock; the significant costs and required management time as a result of operating as a public company; the fact that the price of Harmony's common stock may be volatile and fluctuate substantially; statements related to our intended share repurchases and repurchase timeframe and the significant costs and required management time as a result of operating as a public company. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 25, 2025, and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250408261652/en/

    Harmony Biosciences Investor Contact:

    Brennan Doyle

    484-539-9700

    [email protected]



    Harmony Biosciences Media Contact:

    Cate McCanless

    202-641-6086

    [email protected]

    Get the next $HRMY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HRMY

    DatePrice TargetRatingAnalyst
    6/2/2025$61.00Outperform
    Oppenheimer
    2/11/2025$55.00Buy
    Deutsche Bank
    12/17/2024$75.00Buy
    H.C. Wainwright
    10/10/2024Outperform
    Raymond James
    9/10/2024$56.00Buy
    UBS
    6/21/2024$48.00Buy
    Citigroup
    1/2/2024$30.00Neutral → Underperform
    BofA Securities
    9/25/2023$40.00 → $31.00Neutral → Sell
    Goldman
    More analyst ratings

    $HRMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

      BP1.15205 is a potentially best-in-class OX2R agonist being investigated in narcolepsy and other central disorders of hypersomnolence A first-in-human study is planned to start in 2H 2025; topline clinical data is anticipated in 2026 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the presentation of preclinical pharmacological effect data for BP1.15205, an investigational, highly potent, and potentially best-in-class orexin 2 receptor (OX2R) agonist, which demonstrated significant wake-promoting and cataplexy-suppressing effects in a standard transgenic mouse model of narcolepsy type 1. The data will be presented at the 39th Annual Meeting of the Associated Professiona

      6/11/25 8:05:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

      Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin's Abbreviated New Drug Application (ANDA) for a generic version of WAKIX® (pitolisant hydrochloride). As part of the agreement, litigation in the United States District Court for the District of Delaware will be dismissed, and Lupin will receive a license to launch its generic product no earlier than January 2030 (or July 2030 with pediatric exclusivity), or earlier under certain circumstances. Harmony had asserted multiple patents covering its WAKIX® (pitolisant HCl) product, the first and only non-scheduled FDA-approve

      6/5/25 8:05:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

      Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL on Monday, June 9, 2025, at 3:20 p.m., ET A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overl

      6/4/25 8:05:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer resumed coverage on Harmony Biosciences with a new price target

      Oppenheimer resumed coverage of Harmony Biosciences with a rating of Outperform and set a new price target of $61.00

      6/2/25 8:52:53 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Harmony Biosciences with a new price target

      Deutsche Bank initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $55.00

      2/11/25 7:08:06 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Harmony Biosciences with a new price target

      H.C. Wainwright initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $75.00

      12/17/24 8:37:30 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Sabater Juan A.

      4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

      5/16/25 4:05:59 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gracias Antonio J.

      4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

      5/16/25 4:05:30 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Philip Ron M

      4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

      5/16/25 4:04:33 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRMY
    Financials

    Live finance-specific insights

    See more
    • Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​

      WAKIX® (pitolisant) Net Revenue of $184.7 Million for First Quarter 2025; Representing 20% Growth Year-over-Year; Reiterates Guidance of $820-$860M​ Net Income Grew 19% Year-over-Year, Building on Four Consecutive Years of Profitability; Increased Cash and Investments to Over $600 Million on Balance Sheet Completed Recruitment of Phase 3 Registrational Trial of ZYN002 in Fragile X Syndrome; On Track for Topline Data in Q3 BP1.15205, Potential Best in Class Orexin, Data to Be Presented at SLEEP 2025 Conference in June On Track for Initiation of Next-Generation Pitolisant-HD Phase 3 Registrational Trials in Narcolepsy & IH in Q4 ​Conference Call and Webcast to be Held Today at

      5/6/25 7:30:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

      Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 6, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-267-6316 (domestic) or 203-518-9783 (international), and reference passcode HRMYQ125. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceu

      4/29/25 8:05:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs

      WAKIX® (pitolisant) Net Revenue of $201.3 Million for Fourth Quarter and $714.7 Million for Full Year 2024; Representing Growth of 23% in Year-Five on the Market 2025 WAKIX Net Revenue Guidance Between $820 - $860 Million; On Track toward a Potential $1 Billion+ Opportunity Committed to Leadership in Sleep/Wake with Next Generation Pitolisant Formulations and Orexin 2 Receptor Agonist; Phase 3 Registrational Trials with Pitolisant HD in Narcolepsy and IH to Initiate in Q4 2025 Topline Data Readout from Phase 3 Registrational Trial with ZYN002 in Fragile X Syndrome On Track for Q3 2025 Pitolisant Patent Position Strengthened with Favorable Settlement of First Generic Litigation Con

      2/25/25 7:30:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

      SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

      2/13/24 7:06:51 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

      SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

      2/13/24 5:06:22 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

      SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

      2/9/24 9:03:03 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRMY
    SEC Filings

    See more
    • Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

      6/11/25 8:30:15 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

      6/5/25 8:30:13 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Harmony Biosciences Holdings Inc.

      144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

      5/16/25 4:21:54 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRMY
    Leadership Updates

    Live Leadership Updates

    See more
    • Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

      Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark Therapeutics, where he led the commercial launch of a novel gene therapy to treat an inherited form of blindness, expanded its therapeutic platform to larger disease areas, and acquired new technologies and assets through business developm

      4/3/25 8:05:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

      Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company's current CCO, Jeffrey Dierks, is voluntarily stepping down for personal reasons. Zaeske brings 25 years of global leadership across the pharmaceutical industry, building teams and transforming organizations in both the U.S. and Europe. He has broad functional experience spanning commercial strategy and operations, sales, marketing, market access, new product planning and finance. At Harmony, Zaeske will be responsible for leading the company's commercial organization, setting commercial strate

      3/24/25 8:05:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HARMONY BIOSCIENCES APPOINTS JEFFREY M. DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN

      PLYMOUTH MEETING, Pa., Jan. 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another opportunity. The Harmony Board of Directors has named Jeffrey M. Dayno, MD, Harmony's Executive Vice President and Chief Medical Officer, as interim CEO effective immediately. Jeff Aronin, Harmony's founder and Board chairman, will continue to lead the Board of Directors as well as

      1/6/23 4:39:00 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care